Alkermes PLC (NASDAQ:ALKS) “Neutral” Rating Kept Today By UBS; The Price Target is Set to $54

November 7, 2017 - By Vivian Park

 Alkermes PLC (NASDAQ:ALKS)

Investors sentiment increased to 1.12 in Q2 2017. Its up 0.01, from 1.11 in 2017Q1. It improved, as 33 investors sold Alkermes Plc shares while 72 reduced holdings. 41 funds opened positions while 77 raised stakes. 143.16 million shares or 1.87% more from 140.52 million shares in 2017Q1 were reported.

Morgan Stanley invested in 0% or 53,131 shares. Aperio Grp Lc accumulated 0.01% or 25,440 shares. Bnp Paribas Asset Mgmt Hldg Sa holds 0.44% of its portfolio in Alkermes Plc (NASDAQ:ALKS) for 850,195 shares. Pennsylvania-based Smithfield Trust has invested 0% in Alkermes Plc (NASDAQ:ALKS). Hanseatic Svcs Incorporated, a New Mexico-based fund reported 264 shares. Moreover, Federated Invsts Pa has 0.07% invested in Alkermes Plc (NASDAQ:ALKS). Utd Service Automobile Association stated it has 192,952 shares or 0.03% of all its holdings. Citigroup holds 62,792 shares. Commonwealth Equity reported 4,218 shares stake. Toronto Dominion Commercial Bank accumulated 1,875 shares or 0% of the stock. Rhumbline Advisers stated it has 0.02% of its portfolio in Alkermes Plc (NASDAQ:ALKS). Winslow Evans Crocker, a Massachusetts-based fund reported 100 shares. 1,084 were accumulated by Peak6 Investments L P. Cornerstone Advsr has invested 0.02% of its portfolio in Alkermes Plc (NASDAQ:ALKS). Andra Ap reported 0.03% of its portfolio in Alkermes Plc (NASDAQ:ALKS).

Alkermes PLC (NASDAQ:ALKS) Rating Reaffirmed

UBS now has a $54 price target on the $7.31B market cap company or 13.59 % upside potential. In a note shared with investors and clients on Friday morning, Alkermes PLC (NASDAQ:ALKS) shares have had their “Neutral” Rating reiterated by research professionals at UBS.

Investors sentiment increased to 1.12 in Q2 2017. Its up 0.01, from 1.11 in 2017Q1. It improved, as 33 investors sold Alkermes Plc shares while 72 reduced holdings. 41 funds opened positions while 77 raised stakes. 143.16 million shares or 1.87% more from 140.52 million shares in 2017Q1 were reported.

Morgan Stanley invested in 0% or 53,131 shares. Aperio Grp Lc accumulated 0.01% or 25,440 shares. Bnp Paribas Asset Mgmt Hldg Sa holds 0.44% of its portfolio in Alkermes Plc (NASDAQ:ALKS) for 850,195 shares. Pennsylvania-based Smithfield Trust has invested 0% in Alkermes Plc (NASDAQ:ALKS). Hanseatic Svcs Incorporated, a New Mexico-based fund reported 264 shares. Moreover, Federated Invsts Pa has 0.07% invested in Alkermes Plc (NASDAQ:ALKS). Utd Service Automobile Association stated it has 192,952 shares or 0.03% of all its holdings. Citigroup holds 62,792 shares. Commonwealth Equity reported 4,218 shares stake. Toronto Dominion Commercial Bank accumulated 1,875 shares or 0% of the stock. Rhumbline Advisers stated it has 0.02% of its portfolio in Alkermes Plc (NASDAQ:ALKS). Winslow Evans Crocker, a Massachusetts-based fund reported 100 shares. 1,084 were accumulated by Peak6 Investments L P. Cornerstone Advsr has invested 0.02% of its portfolio in Alkermes Plc (NASDAQ:ALKS). Andra Ap reported 0.03% of its portfolio in Alkermes Plc (NASDAQ:ALKS).

Alkermes Plc (NASDAQ:ALKS) Ratings Coverage

Among 13 analysts covering Alkermes (NASDAQ:ALKS), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Alkermes has $85 highest and $35 lowest target. $64.25’s average target is 35.15% above currents $47.54 stock price. Alkermes had 33 analyst reports since September 1, 2015 according to SRatingsIntel. The stock of Alkermes Plc (NASDAQ:ALKS) earned “Hold” rating by Leerink Swann on Thursday, July 27. The stock of Alkermes Plc (NASDAQ:ALKS) earned “Buy” rating by J.P. Morgan on Thursday, June 29. The rating was maintained by Barclays Capital on Friday, July 29 with “Overweight”. Leerink Swann maintained it with “Outperform” rating and $70 target in Friday, October 21 report. The stock of Alkermes Plc (NASDAQ:ALKS) has “Neutral” rating given on Thursday, January 21 by JP Morgan. The firm earned “Hold” rating on Thursday, October 26 by Cantor Fitzgerald. The stock of Alkermes Plc (NASDAQ:ALKS) earned “Outperform” rating by Leerink Swann on Thursday, January 21. The stock of Alkermes Plc (NASDAQ:ALKS) has “Buy” rating given on Thursday, August 24 by Jefferies. The firm has “Buy” rating by Jefferies given on Friday, October 21. Cowen & Co downgraded the stock to “Market Perform” rating in Thursday, January 21 report.

About 230,693 shares traded. Alkermes Plc (NASDAQ:ALKS) has risen 47.50% since November 7, 2016 and is uptrending. It has outperformed by 30.80% the S&P500.

Alkermes plc is a biopharmaceutical company. The company has market cap of $7.31 billion. The Firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. It currently has negative earnings. The Firm has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

More notable recent Alkermes Plc (NASDAQ:ALKS) news were published by: Prnewswire.com which released: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of …” on November 07, 2017, also Bloomberg.com with their article: “Senator Investigates How Drugmaker Alkermes Pushed Its Opioid-Addiction Treatment” published on November 06, 2017, Seekingalpha.com published: “Alkermes Stands To Gain From Revenue Increase, Upcoming NDA Submission” on October 16, 2017. More interesting news about Alkermes Plc (NASDAQ:ALKS) were released by: Streetinsider.com and their article: “Alkermes plc (ALKS) Presents Data Demonstrating Safety and Gastrointestinal …” published on October 27, 2017 as well as Streetinsider.com‘s news article titled: “Alkermes plc (ALKS) Launches Investigational Product Designed for Initiation …” with publication date: October 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.